Trial · NCT07907237
Registered outcomes23
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 23
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Eligibility rate, defined as the number of eligible participants relative to the number of patients in the ICU |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Enrollment rate, defined as the number of participants enrolled in the study relative to the number of eligible patients |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Initiation rate, defined as the number of included participants who complete at least one session |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Number of completed sessions |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Setup and session duration |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Rate of completed sessions relative to the number of scheduled sessions |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Technical failure rate (malfunction, calibration difficulties, anatomical incompatibility) |
| Primary | Feasibility of Exoskeleton-Assisted Rehabilitation | Up to 14 days | Reasons for session termination |
| Secondary | Patient acceptability | Up to 14 days | number of initial refusals |
| Secondary | Patient acceptability | Up to 14 days | the dropout rate |
| Secondary | Participant satisfaction levels | Up to 14 days | mean Visual Analogue Scale (VAS) score |
| Secondary | Perceived effort during each session | Up to 14 days | mean Visual Analogue Scale (VAS) score |
| Secondary | Acceptability from the team's perspective | Up to 14 days | Mean NASA-TLX Load Index score |
| Secondary | Safety | Up to 14 days | Rate of serious adverse events |
| Secondary | Safety | Up to 14 days | Rate of non-serious adverse events |
| Secondary | Discontinuation criteria | Up to 14 days | Observed discontinuation criteria, n (%) |
| Secondary | Efficacy (muscle function during treatment) | Baseline and 1 month | Assessment of muscle function during treatment: changes in walking time |
| Secondary | Efficacy (muscle function during treatment) | Baseline and 1 month | session duration at the beginning and end of treatment |
| Secondary | Efficacy | Baseline and 1 month | Number of squats performed per session |
| Secondary | Efficacy | Baseline and 1 month | Average percentage of exoskeleton assistance per session and per leg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07907237/registered